Evolution and neutralization escape of the SARS-CoV-2 BA.2.86 subvariant
Omicron BA.2.86 subvariant differs from Omicron BA.2 as well as recently circulating variants by over 30 mutations in the spike protein alone. Here we report on the first isolation of the live BA.2.86 subvariant from a diagnostic swab collected in South Africa which we tested for escape from neutralizing antibodies and viral replication properties in cell culture. BA.2.86 did not have significantly more escape than Omicron XBB.1.5 from neutralizing immunity elicited by infection of Omicron subvariants ranging from BA.1 to XBB, either by infection alone or as breakthrough infection in vaccinated individuals. Neutralization escape was present relative to earlier strains: BA.2.86 showed extensive escape both relative to ancestral virus in sera from pre-Omicron vaccinated individuals and relative to Omicron BA.1 in sera from Omicron BA.1 infected individuals. We did not observe substantial differences in viral properties in cell culture relative to XBB.1.5. Both BA.2.86 and XBB.1.5 produced infection foci of similar size, had similar cytopathic effect (both lower than ancestral SARS-CoV-2), and had similar replication dynamics. We also investigated the relationship of BA.2.86 to BA.2 sequences and found that the closest were BA.2 samples from Southern Africa circulating in early 2022. These observations suggest that BA.2.86 is more closely related to sequences from Southern Africa than other regions and so may have evolved there, and that evolution led to escape from neutralizing antibodies similar in scale to recently circulating strains of SARS-CoV-2..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
bioRxiv.org - (2024) vom: 23. Apr. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Khan, Khadija [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| doi: |
10.1101/2023.09.08.23295250 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI040790673 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI040790673 | ||
| 003 | DE-627 | ||
| 005 | 20240424104837.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230910s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2023.09.08.23295250 |2 doi | |
| 035 | |a (DE-627)XBI040790673 | ||
| 035 | |a (biorXiv)10.1101/2023.09.08.23295250 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Khan, Khadija |e verfasserin |0 (orcid)0000-0001-7565-7400 |4 aut | |
| 245 | 1 | 0 | |a Evolution and neutralization escape of the SARS-CoV-2 BA.2.86 subvariant |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Omicron BA.2.86 subvariant differs from Omicron BA.2 as well as recently circulating variants by over 30 mutations in the spike protein alone. Here we report on the first isolation of the live BA.2.86 subvariant from a diagnostic swab collected in South Africa which we tested for escape from neutralizing antibodies and viral replication properties in cell culture. BA.2.86 did not have significantly more escape than Omicron XBB.1.5 from neutralizing immunity elicited by infection of Omicron subvariants ranging from BA.1 to XBB, either by infection alone or as breakthrough infection in vaccinated individuals. Neutralization escape was present relative to earlier strains: BA.2.86 showed extensive escape both relative to ancestral virus in sera from pre-Omicron vaccinated individuals and relative to Omicron BA.1 in sera from Omicron BA.1 infected individuals. We did not observe substantial differences in viral properties in cell culture relative to XBB.1.5. Both BA.2.86 and XBB.1.5 produced infection foci of similar size, had similar cytopathic effect (both lower than ancestral SARS-CoV-2), and had similar replication dynamics. We also investigated the relationship of BA.2.86 to BA.2 sequences and found that the closest were BA.2 samples from Southern Africa circulating in early 2022. These observations suggest that BA.2.86 is more closely related to sequences from Southern Africa than other regions and so may have evolved there, and that evolution led to escape from neutralizing antibodies similar in scale to recently circulating strains of SARS-CoV-2. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Lustig, Gila |e verfasserin |4 aut | |
| 700 | 1 | |a Reedoy, Kajal |e verfasserin |4 aut | |
| 700 | 1 | |a Jule, Zesuliwe |e verfasserin |4 aut | |
| 700 | 1 | |a Römer, Cornelius |e verfasserin |4 aut | |
| 700 | 1 | |a Karim, Farina |e verfasserin |4 aut | |
| 700 | 1 | |a Ganga, Yashica |e verfasserin |4 aut | |
| 700 | 1 | |a Bernstein, Mallory |e verfasserin |4 aut | |
| 700 | 1 | |a Baig, Zainab |e verfasserin |4 aut | |
| 700 | 1 | |a Mahlangu, Boitshoko |e verfasserin |4 aut | |
| 700 | 1 | |a Mnguni, Anele |e verfasserin |4 aut | |
| 700 | 1 | |a Nzimande, Ayanda |e verfasserin |4 aut | |
| 700 | 1 | |a Stock, Nadine |e verfasserin |4 aut | |
| 700 | 1 | |a Kekana, Dikeledi |e verfasserin |4 aut | |
| 700 | 1 | |a Ntozini, Buhle |e verfasserin |4 aut | |
| 700 | 1 | |a van Deventer, Cindy |e verfasserin |4 aut | |
| 700 | 1 | |a Marshall, Terry |e verfasserin |4 aut | |
| 700 | 1 | |a Manickchund, Nithendra |e verfasserin |4 aut | |
| 700 | 1 | |a Gosnell, Bernadett I. |e verfasserin |4 aut | |
| 700 | 1 | |a Lessells, Richard J. |e verfasserin |4 aut | |
| 700 | 1 | |a Abdool Karim, Quarraisha |e verfasserin |4 aut | |
| 700 | 1 | |a Abdool Karim, Salim S. |e verfasserin |4 aut | |
| 700 | 1 | |a Moosa, Mahomed-Yunus S. |e verfasserin |4 aut | |
| 700 | 1 | |a de Oliveira, Tulio |e verfasserin |0 (orcid)0000-0002-3027-5254 |4 aut | |
| 700 | 1 | |a von Gottberg, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Wolter, Nicole |e verfasserin |4 aut | |
| 700 | 1 | |a Neher, Richard A |e verfasserin |0 (orcid)0000-0003-2525-1407 |4 aut | |
| 700 | 1 | |a Sigal, Alex |e verfasserin |0 (orcid)0000-0001-8571-2004 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2024) vom: 23. Apr. |
| 773 | 1 | 8 | |g year:2024 |g day:23 |g month:04 |
| 856 | 4 | 0 | |u https://doi.org/10.1038/s41467-023-43703-3 |x 0 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2023.09.08.23295250 |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 23 |c 04 | ||